SCHEMBL1338038

SCHEMBL1338038

Cn1c(=O)c(-c2ccc(Br)cc2)cc2c3cc(-c4nc(CCl)cs4)ccc3n(C)c21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 6/20 0.41
▸ ALDH1A1 P00352 5/20 0.41
▸ MAPT P10636 5/20 0.41
▸ GFER P55789 2/20 0.41
▸ RXFP1 Q9HBX9 2/20 0.41
▸ PPARG P37231 1/20 0.41
▸ NCOA2 Q15596 1/20 0.41
▸ NCOA1 Q15788 1/20 0.41
▸ KDM4E B2RXH2 6/20 0.40
▸ TDP1 Q9NUW8 3/20 0.40
▸ RAB9A P51151 3/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ POLB P06746 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ SREBF2 Q12772 1/20 0.38
▸ ENPP2 Q13822 7/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.37
▸ RECQL P46063 1/20 0.37
▸ ATM Q13315 1/20 0.37
▸ SMN1; SMN2 Q16637 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1339064 0.90 SREBF2 (0.38) LMNAALDH1A1MAPTRXFP1KDM4E
SCHEMBL1338957 0.84 GFER (0.44) LMNAALDH1A1MAPTGFERRXFP1
SCHEMBL1338699 0.84 ENPP2 (0.38) SREBF2ENPP2
SCHEMBL1339356 0.82 LMNA (0.43) LMNAALDH1A1SREBF2ENPP2L3MBTL1
SCHEMBL1339172 0.79 LMNA (0.40) LMNAALDH1A1MAPTSREBF2ENPP2
SCHEMBL1338217 0.78 SHMT1 (0.40) LMNARXFP1KDM4ERAB9ANPC1
SCHEMBL1338328 0.77 LMNA (0.39) LMNAALDH1A1MAPTKDM4ERAB9A
SCHEMBL1336852 0.76 SHMT1 (0.38) LMNAALDH1A1GFERRXFP1KDM4E
SCHEMBL1338195 0.75 SHMT1 (0.37) LMNAALDH1A1RXFP1KDM4ERAB9A
SCHEMBL1339424 0.75 SHMT1 (0.47) LMNAALDH1A1KDM4ERAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed
EP-1940840-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2008-07-09 — — EP disclosed
WO-2007045758-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2007-04-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 LMNA 2367/4885ALDH1A1 283/4885MAPT 2476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback